Elevated DPP4 expression has been linked to insulin resistance in obesity [45] and NAFLD [35], and DPP4 inhibitors are currently in clinical use as anti-diabetic drugs. Here, DPP4 is linked to obesity due to melanocortin 4 receptor deficiency.